Nektar Therapeutics to Report Third-Quarter 2026 Results on November 12 After Market Close

Nektar Therapeutics will announce its third-quarter 2026 financial results on November 12, after U.S. markets close, the company said in a TradingView release. The results cover the quarter ended September 30, 2026. CEO Howard Robin will host a conference call at 5:00 p.m. Eastern Time, or 2:00 p.m. Pacific Time.

How Nektar's Third-Quarter Call Will Run

Nektar Therapeutics is a San Francisco-based clinical-stage biotechnology company developing treatments for immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin, is a regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata and Type 1 diabetes mellitus. The pipeline also includes preclinical TNFR2 antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified CSF protein, NKTR-422.

The press release and a live audio-only webcast will be accessible through a link posted on the home page and investors section of the company's website. A replay of the web broadcast will be available through December 12, 2026. Call participants must pre-register to receive dial-in information and a PIN.

Nektar's April Offering and Phase 3 Plans

According to akta.pro company records, Nektar closed a $373.8 million underwritten public offering in April 2026, selling 4,062,500 shares at $92.00 per share to fund Phase 3 trials of rezpegaldesleukin in atopic dermatitis and alopecia areata. The same records show a February 2026 underwritten offering of common stock and pre-funded warrants that raised $460 million, selling 7,637,931 shares at $58.00 per share plus 293,103 pre-funded warrants. The records list 11 funding rounds, with total funding of $2.4 billion and a last round dated April 21, 2026.

Nektar's Recent Lawsuit Win and Analyst Pick

On October 7, 2026, Yahoo reported that Nektar won a lawsuit against Eli Lilly, receiving $90 million in damages plus interest, totaling about $115 million. On October 12, 2026, Seeking Alpha reported that Leerink Partners named Nektar, Protagonist Therapeutics and Shattuck Labs as its top stock picks in the emerging immunology sector. On October 20, 2026, Nektar granted 45,750 stock options and 2,775 restricted stock units to 16 newly hired employees under its 2025 Inducement Plan, Stock Titan reported.

What Follows Nektar's November 12 Call

The webcast replay will remain available through December 12, 2026.